Comparative analysis of second and third-generation nanobody-based CAR-NK cells targeting PSMA in prostate cancer immunotherapy: In silico and in vitro studies

Objective(s): The use of CAR technology in the treatment of cancer cells is progressing, as well as the use of CAR T-cell in the treatment of blood malignancies is in the clinical trial stage.  In this study, have compared the second and third generation CAR expressed in NK cells in dealing with pro...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Masoud Gandomkar Ghalhar, Arezoo Karami Vandishi, Akram Ramazani, Fatemeh Hajari Taheri, Zahra Sharifzadeh, Mohsen Abolhassani, Masoud Soleimani, Niloofar Taghipour, Wytske M van Weerden, Mojgan Bandehpour, Mahmoud Hassani, Kowsar Bagherzadeh
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Mashhad University of Medical Sciences 2026-07-01
Rangatū:	Iranian Journal of Basic Medical Sciences
Ngā marau:	chimeric antigen receptor natural killer cell single-domain antibodies (nanobodies) prostate-specific membrane antigen (psma) prostatic neoplasms ox40 co-stimulatory domain molecular dynamics - simulation
Urunga tuihono:	https://ijbms.mums.ac.ir/article_27812_f212a03a8006e33d9ba51817faf950c8.pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!